Feeds
20859 items (20859 unread) in 74 feeds
Acinar Cell Carcinoma
(201 unread)
Acinic Cell Carcinoma
(104 unread)
Adenoid Cystic Carcinoma
(367 unread)
Adrenal Gland Cancer
(1718 unread)
Ampulla Of Vater
(213 unread)
Anal Cancer
(1799 unread)
Angiosarcoma
(359 unread)
Appendix Cancer
(450 unread)
Bile Duct Cancer
(2698 unread)
Brain and CNS
(2597 unread)
Carcinoid
(671 unread)
Endocrine/Neuroendocrine
(2404 unread)
Gall Bladder Cancer
(1146 unread)
Hemangioendothelioma
(506 unread)
Hepatoblastoma
(366 unread)
Pancreas
(416 unread)
Phyllodes
(215 unread)
PMP and Mucinous Tumors
(242 unread)
Rhabdomyosarcoma
(772 unread)
Sarcoma
(3615 unread)
Google - Neuroendocrine Tumor (100 unread)
-
Surufatinib Approved in China for Advanced Pancreatic Neuroendocrine Tumors - OncLive
Posted: June 18th, 2021, 7:07pm GMT
-
Gesture Recognition Market 2021-2027 Global Industry Analysis – The Courier - The Courier
Posted: June 18th, 2021, 10:36am GMT
-
Europe Neuroendocrine Tumors Market Share, Major Manufacturers, Countries and Growth To 2028 || Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries
Posted: June 18th, 2021, 10:21am GMT
-
Pancreatic neuroendocrine carcinoma in a pregnant woman: A case report and review of the literature - DocWire News
Posted: June 18th, 2021, 4:00am GMT
-
Neuroendocrine Tumor Drug Market 2021-2026 Industry Size and Share, Recent Enhancements and Regional Analysis | Key Vendors: Eisai, Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceutical - Clark C
Posted: June 18th, 2021, 11:22pm GMT
-
Neuroendocrine Carcinoma Market 2021 | Global Industry Research on Growth, Trends, Business Opportunity and Top Companies Analysis in 2021-2028 | Ipsen Pharma, Mateon Therapeutics, Inc, Mallinckrodt, Amgen Inc – The Courier - The Courier
Posted: June 17th, 2021, 5:43pm GMT
-
Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market 2021 Development Status – Novartis, Pfizer, Fresenius Kabi, Teva Pharmaceuticals – The Manomet Current - The Manomet Current
Posted: June 17th, 2021, 11:53am GMT
-
Somatostatin Analogs Market 2021 Research and Clinical Analysis - openPR
Posted: June 16th, 2021, 1:58pm GMT
-
FOLFOX Chemotherapy: Uses, Procedure, Side Effects & More - Healthline
Posted: June 16th, 2021, 1:07pm GMT
-
Oncology Leaves Its Mark on 2020 Research and Development Trends - OncLive
Posted: June 16th, 2021, 12:10pm GMT
-
Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) – Market 2021 | Extensive Growth | Opportunities | Impact and Precise Outlook 2029 – Merck & Co., Inc and Pfizer Inc. – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
Posted: June 16th, 2021, 11:51am GMT
-
Identification of liver cancer stem cell stemness markers | SCCAA - Dove Medical Press
Posted: June 15th, 2021, 9:07pm GMT
Identification of liver cancer stem cell stemness markers | SCCAA Dove Medical Press -
Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms - MD Linx
Posted: June 15th, 2021, 12:37pm GMT
-
Viewpoint Molecular Targeting(TM) Chief Scientific Officer, Dr. Michael Schultz, Discusses the Promise of Image-Guided 212Pb Alpha-Particle Radiopharmaceutical Therapies for Cancer at the SNMMI 2021 Annual Meeting - Digital Journal
Posted: June 15th, 2021, 11:26am GMT
-
Global Neuroendocrine Tumor Treatment Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application – The Manomet Current - The Manomet Current
Posted: June 15th, 2021, 6:39am GMT
-
Neuroendocrine Neoplasms of the Gallbladder: A Clinicopathological Analysis of 13 Patients and a Review of the Literature - DocWire News
Posted: June 15th, 2021, 5:29am GMT
-
Neuroendocrine Tumor Treatment Market Advancement Status, Revenue Assessment to 2030 Research Report| Novartis AG, Ipsen SA, Advanced Accelerator Applications SA – The Courier - The Courier
Posted: June 15th, 2021, 5:21am GMT
-
Long non-coding RNA AFAP1-AS1 facilitates prostate cancer progression by regulating miR-15b/IGF1R axis - DocWire News
Posted: June 15th, 2021, 4:00am GMT
-
Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting - Galveston County Daily News
Posted: June 14th, 2021, 10:32am GMT
-
Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting - Business Wire
Posted: June 14th, 2021, 10:30am GMT
-
Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting - Benzinga
Posted: June 14th, 2021, 10:30am GMT
-
Dental Obturators Market 2021 | Size, Share, Growth, Analysis, Trends, Competitive Landscape, Revenue, Forecast Report - GlobeNewswire
Posted: June 14th, 2021, 7:13am GMT
-
High SQLE expression and gene amplification | CMAR - Dove Medical Press
Posted: June 13th, 2021, 8:22pm GMT
High SQLE expression and gene amplification | CMAR Dove Medical Press -
Predicting Survival in Malignant Pleural Effusion - CMAR | CMAR - Dove Medical Press
Posted: June 13th, 2021, 8:16pm GMT
Predicting Survival in Malignant Pleural Effusion - CMAR | CMAR Dove Medical Press -
Neuroendocrine Tumor Drug Market 2021-2026 : Regional Outlook in Neuroendocrine Tumor Drug Industry | Top Companies: Jiangsu Hengrui Medicine Co., Ltd., Eisai, Hutchison MediPharma Limited, Exelixis, Inc., Ipsen SA, Foresee Pharmaceuticals, LLC, - Clark
Posted: June 13th, 2021, 7:35pm GMT
-
ASCO 2021 recap: Lynparza's lift, Grail goes on, LAG validation & more - MedCity News
Posted: June 13th, 2021, 12:23pm GMT
-
Cedars-Sinai Cancer names thoracic medical oncology director - Healio
Posted: June 13th, 2021, 9:47am GMT
-
Business Overview of Neuroendocrine Tumor Treatment Industry Size, Global Market Trends and Forecast to 2021-2026 – Clark County Blog - Clark County Blog
Posted: June 13th, 2021, 12:54am GMT
-
Anne Nathan Obituary (2021) - Buffalo Grove, IL - Chicago Tribune - Legacy.com
Posted: June 12th, 2021, 3:45am GMT
-
Ga 68 DOTATOC Market By 2030 Top Winning Strategies, COVID-19 Impacting Factors, Business Strategies | Future Market Insights - Industry Today
Posted: June 11th, 2021, 3:38pm GMT
-
Theranostics: a new hope in the fight against cancer - EL PAÍS in English
Posted: June 11th, 2021, 12:58pm GMT
Theranostics: a new hope in the fight against cancer EL PAÍS in English -
Neuroendocrine Tumor Treatment Market Development, Business Strategies 2021 with Top Key Players – Pfizer Inc, Novartis AG, Ipsen etc. – The Manomet Current - The Manomet Current
Posted: June 11th, 2021, 12:55pm GMT
-
Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine‐non‐neuroendocrine neoplasm - MD Linx
Posted: June 11th, 2021, 10:11am GMT
-
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids - DocWire News
Posted: June 11th, 2021, 4:00am GMT
-
Babil Khan shares unseen photos of Irrfan and family: Take that chance to tell them you love them back - The Indian Express
Posted: June 11th, 2021, 12:44am GMT
-
Lung Cancer Therapeutics Market Segmentation, Parameters, Prospects 2021 And Forecast Research Report To 2027 – The Manomet Current - The Manomet Current
Posted: June 10th, 2021, 5:36pm GMT
-
Who Is 'AGT' Contestant Nightbirde? - PopCrush
Posted: June 10th, 2021, 4:11pm GMT
Who Is 'AGT' Contestant Nightbirde? PopCrush -
Update sustains strong activity with belzutifan in VHL-associated kidney cancer - Urology Times
Posted: June 10th, 2021, 2:26pm GMT
-
Retinal Biologics Market worth USD 34,891.44 Million by - GlobeNewswire
Posted: June 10th, 2021, 1:21pm GMT
Retinal Biologics Market worth USD 34,891.44 Million by GlobeNewswire -
Retinal Biologics Market worth USD 34891.44 Million by 2027, at 11.5% CAGR | Market Research Future (MRFR) - EIN News
Posted: June 10th, 2021, 1:21pm GMT
-
Molecular Profiling in Pediatric Cancer Trials Continues to Prove Valuable for Treatment Matching - Precision Oncology News
Posted: June 10th, 2021, 12:43pm GMT
-
Viewpoint Molecular Targetin(TM) Commences Patient Enrollment in Phase 1 Imaging Study for VMT01 Program for Metastatic Melanoma - Digital Journal
Posted: June 10th, 2021, 12:32pm GMT
-
Viewpoint Molecular Targetin(TM) Commences Patient Enrollment in Phase 1 Imaging Study for VMT01 Program for Metastatic Melanoma - Big News Network
Posted: June 10th, 2021, 12:05pm GMT
-
Neuroendocrine Tumor Treatment Market – Revolutionary Scope by 2026 - Business-newsupdate.com
Posted: June 10th, 2021, 5:50am GMT
Neuroendocrine Tumor Treatment Market – Revolutionary Scope by 2026 Business-newsupdate.com -
Therapy considerations in neuroendocrine prostate cancer: what next? - DocWire News
Posted: June 10th, 2021, 4:00am GMT
-
Teragnosis is the new hope against cancer | Science - brytfmonline.com
Posted: June 10th, 2021, 12:24am GMT
Teragnosis is the new hope against cancer | Science brytfmonline.com -
Belzutifan Shows Strong Responses in RCC and Other VHL-Associated Lesions - Targeted Oncology
Posted: June 9th, 2021, 8:51pm GMT
-
Biomarker Uncovered by Roswell Park Team Identifies NET Patients Likely to Have Blood Side Effects from PRRT - Newswise
Posted: June 9th, 2021, 2:10pm GMT
-
Awards & Accolades: May 2021 - pennmedicine.org
Posted: June 9th, 2021, 10:57am GMT
Awards & Accolades: May 2021 pennmedicine.org -
Subtle Medical Receives CE Mark for SubtlePET™ 2.0 to Expand Improved PET Imaging Capabilities - BioSpace
Posted: June 9th, 2021, 9:47am GMT
-
Neuroendocrine Tumors Treatment Market to Reflect Steady Growth Rate by 2027 – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
Posted: June 9th, 2021, 6:50am GMT
Neuroendocrine Tumors Treatment Market to Reflect Steady Growth Rate by 2027 – KSU | The Sentinel Newspaper KSU | The Sentinel Newspaper -
Response to pegylated interferon in a COVID‐19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus - Wiley
Posted: June 9th, 2021, 5:00am GMT
-
Response to pegylated interferon in a COVID‐19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus - Wiley
Posted: June 9th, 2021, 5:00am GMT
-
Middle East and Africa Neuroendocrine Tumors Market 2021| Top Manufactures Industry Size, Growth, Analysis and Forecast 2028 – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
Posted: June 9th, 2021, 3:28am GMT
-
Europe Neuroendocrine Tumors Market 2021 COVID-19 Impact Analysis, Key Players, Segmentation, Application And Forecast By 2028 – The Courier - The Courier
Posted: June 9th, 2021, 3:24am GMT
-
Teragnosis: a new hope against cancer | Science - The Saxon
Posted: June 9th, 2021, 1:57am GMT
-
Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size and Growth 2027 | Key Players – Novartis, Tarveda Therapeutics, Teva Pharmaceuticals, Pfizer, Exelixis – Clark County Blog - Clark County Blog
Posted: June 8th, 2021, 9:53pm GMT
-
Teacher, media specialist, coach - The Torrington Telegram
Posted: June 8th, 2021, 8:41pm GMT
Teacher, media specialist, coach The Torrington Telegram -
Neuroendocrine Tumors Market 2021 Industry Trends, Growth, COVID-19 Impact Analysis, Opportunities And Overview 2021 – 2028 – The Manomet Current - The Manomet Current
Posted: June 8th, 2021, 4:19pm GMT
-
North America Neuroendocrine Tumors Market Trends by Key Players, End User, Demand, Analysis Growth and Forecast 2028 – The Manomet Current - The Manomet Current
Posted: June 8th, 2021, 4:12pm GMT
-
Europe Neuroendocrine Tumors Market In-Depth Analysis Of Competitive Landscape Executive Summary Development Factors 2028 – The Manomet Current - The Manomet Current
Posted: June 8th, 2021, 2:43pm GMT
-
Middle East and Africa Neuroendocrine Tumors Market Report Analysis And Insights For Highly Profitable Investment Decision: Industry Outlook By 2021-2028 – The Manomet Current - The Manomet Current
Posted: June 8th, 2021, 2:42pm GMT
-
Biomarker Uncovered by Roswell Park Team Identifies NET Patients Likely to Have Blood Side Effects from PRRT - PR Web
Posted: June 8th, 2021, 8:27am GMT
-
Is radioembolization appropriate for patients with limited extrahepatic spread? - Healio
Posted: June 8th, 2021, 5:00am GMT
-
Small-cell neuroendocrine carcinoma of the gynecologic tract | CMAR - Dove Medical Press
Posted: June 7th, 2021, 9:25pm GMT
Small-cell neuroendocrine carcinoma of the gynecologic tract | CMAR Dove Medical Press -
A Tale of Medical Mysteries Unraveled by Genetic Detectives - Medscape
Posted: June 7th, 2021, 4:19pm GMT
-
Neuroendocrine Tumors (NETs) Treatment Market Size and Growth 2027 | Key Players – Advanced Accelerator Applications, Progenics Pharmaceuticals, Hutchison MediPharma Limited, AVEO Oncology, Pfizer – NeighborWebSJ - NeighborWebSJ
Posted: June 7th, 2021, 2:56pm GMT
-
Neuroendocrine Tumor Drug Market Size and Growth 2027 | Key Players – Eisai, Jiangsu Hengrui Medicine , Hutchison MediPharma Limited, Exelixis, Ipsen SA – NeighborWebSJ - NeighborWebSJ
Posted: June 7th, 2021, 2:39pm GMT
-
Clinical Catch-Up: June 1-6 - BioSpace
Posted: June 7th, 2021, 12:32pm GMT
Clinical Catch-Up: June 1-6 BioSpace -
The Importance of the Assessment of Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors to the Field - Pharmacy Times
Posted: June 6th, 2021, 4:19pm GMT
-
Single and Dual Immunotherapy Regimens May Offer Improved Overall Survival in Esophageal Cancer - OncoZine
Posted: June 6th, 2021, 1:39am GMT
-
Assessing the Adverse Events From Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors - Pharmacy Times
Posted: June 5th, 2021, 5:43pm GMT
-
Sukhmani Padda named director of Thoracic Medical Oncology at Cedars-Sinai - The Cancer Letter
Posted: June 4th, 2021, 4:30pm GMT
-
Middle East and Africa Neuroendocrine Tumors Market 2021 Industry Trends, Growth, COVID-19 Impact An - PharmiWeb.com
Posted: June 4th, 2021, 3:15pm GMT
-
Novartis (NVS) Announces Data on Radioligand Therapy at ASCO - Yahoo Finance
Posted: June 4th, 2021, 3:08pm GMT
-
Novartis (NVS) Announces Data on Radioligand Therapy at ASCO - Nasdaq
Posted: June 4th, 2021, 3:08pm GMT
-
Visa's (V) May Operating Metrics Reflect Brisk Business - Nasdaq
Posted: June 4th, 2021, 3:07pm GMT
-
CSX's Board Clears Stock Split to Attract More Investors - Nasdaq
Posted: June 4th, 2021, 2:44pm GMT
-
The Efficacy, Safety of Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors - Pharmacy Times
Posted: June 4th, 2021, 2:19pm GMT
-
Accelerating Precision Medicine for Cancer Patients - Targeted Oncology
Posted: June 4th, 2021, 12:58pm GMT
Accelerating Precision Medicine for Cancer Patients Targeted Oncology -
Xerox (XRX) to Gain From Document Systems Buyout: Here's How - Nasdaq
Posted: June 4th, 2021, 12:43pm GMT
-
Veracyte Bladder Cancer Test Receives Medicare Coverage - GenomeWeb
Posted: June 4th, 2021, 12:26pm GMT
-
Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of - GlobeNewswire
Posted: June 4th, 2021, 11:00am GMT
-
Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors - Business Wire
Posted: June 4th, 2021, 11:00am GMT
-
Global Gastro-Esophageal Junction Neuroendocrine Tumor (GEJ-NET) Market: Latest Innovations, Drivers and Industry Key Events 2020–2029 – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
Posted: June 4th, 2021, 8:49am GMT
-
Kornit Digital (KRNT) Stock Jumps 4.8%: Will It Continue to Soar? - Nasdaq
Posted: June 4th, 2021, 6:07am GMT
-
Novartis reports 'clinically relevant' survival data for Lutathera - PharmaTimes
Posted: June 4th, 2021, 5:48am GMT
-
Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER - GlobeNewswire
Posted: June 3rd, 2021, 7:05pm GMT
-
Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER - GlobeNewswire
Posted: June 3rd, 2021, 7:05pm GMT
-
Vincerx Pharma doses first patient in early-stage VIP152 cancer study - Seeking Alpha
Posted: June 3rd, 2021, 6:12pm GMT
-
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors - StreetInsider.com
Posted: June 3rd, 2021, 6:09pm GMT
-
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed - GlobeNewswire
Posted: June 3rd, 2021, 6:05pm GMT
-
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors - Benzinga
Posted: June 3rd, 2021, 6:05pm GMT
-
Novartis Drug's Radiation Blast Extends Prostate Cancer Survival - Bloomberg
Posted: June 3rd, 2021, 1:53pm GMT
-
Novartis Drug's Radiation Blast Extends Prostate Cancer Survival - swissinfo.ch
Posted: June 3rd, 2021, 11:53am GMT
-
North America Neuroendocrine Tumors Market 2021 | Growth Drivers Challenges, Trends and Industry Dynamics, Forecast 2028 – The Manomet Current - The Manomet Current
Posted: June 3rd, 2021, 8:51am GMT
-
Global Neuroendocrine Tumors Market 2028| Key Vendor Landscape By Regional Output Demand By Countries And Future Growth – The Manomet Current - The Manomet Current
Posted: June 3rd, 2021, 8:51am GMT
-
Sunitinib Malate Market Overview Analysis, Status and Business Outlook till 2027| Pfizer, Topcare pharmaceutical Co. Ltd, Nanjing First Pharmaceutical Co. Ltd., J&K Scientific – The Courier - The Courier
Posted: June 3rd, 2021, 6:12am GMT
-
Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera - PRNewswire
Posted: June 3rd, 2021, 5:00am GMT
-
Novartis Drug’s Radiation Blast Extends Prostate Cancer Survival - BloombergQuint
Posted: June 3rd, 2021, 5:00am GMT